Home
Science & Technology
Publications

Publications:
Our Research

Filter

Filter

Research Area
Technology
Resource type
Category
216 results found
Feb 15, 2024
Publication
Novavax led
Vaccine
COVID-19, Matrix-M® adjuvant
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine
Seth Toback, Anthony M. Marchese, Brandy Warren, et al.
View
Feb 12, 2024
Publication
Novavax led
Journal of Infection
COVID-19, Matrix-M® adjuvant
Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccine
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark , et al.
View
Feb 9, 2024
Publication
Novavax led
Pre-print
COVID-19, Matrix-M® adjuvant
Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Jacco Boon, Nadia Soudani, Traci Bricker, et al.
View
Feb 8, 2024
Publication
Collaborative
bioRxiv
Malaria, Matrix-M® adjuvant
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex
Barnabas G Williams, Lloyd D.W King, David Pulido, et al.
View
Feb 6, 2024
Publication
Collaborative
Vaccine
COVID-19, Matrix-M® adjuvant
The Brighton collaboration standardized module for vaccine benefit-risk assessment
Levitan B, Hadler SC, Hurst W, et al.
View
Feb 2, 2024
Publication
Novavax led
Journal of Virology
COVID-19, Matrix-M® adjuvant
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Traci L. Bricker , Astha Joshi , Nadia Soudani, et al.
View
Jan 30, 2024
Publication
Collaborative
The Journal of Clinical Investigation
Malaria, Matrix-M® adjuvant
A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults
B. Alfred Tiono, Jordan Plieskatt, Alphonse Ouedraogo, et al.
View
Jan 24, 2024
Publication
Novavax led
Vaccine
COVID-19, Matrix-M® adjuvant
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States
Kyle Paret, Hadi Beyhaghi, William L. Herring, et al.
View
Jan 24, 2024
Publication
Novavax led
Vaccine
COVID-19, Matrix-M® adjuvant
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study
Matthew Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
View
Jan 20, 2024
Publication
Collaborative
npj Vaccines
COVID-19, Matrix-M® adjuvant
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2
Lenart K, Arcoverde Cerveira R, Hellgren F, et al.
View